| dc.contributor.author | Mathebula, Lindi | |
| dc.contributor.author | Mapahla, Lovemore | |
| dc.contributor.author | Jordan, Esme | |
| dc.date.accessioned | 2022-07-12T08:01:21Z | |
| dc.date.available | 2022-07-12T08:01:21Z | |
| dc.date.issued | 2022 | |
| dc.identifier.citation | Mathebula, L. et al. (2022). Planned, ongoing and completed tuberculosis treatment trials in Brazil, Russia, India, China and South Africa: A 2019 cross-sectional descriptive analysis. . BMJ Open, 12, e057941. 10.1136/ bmjopen-2021-057941 | en_US |
| dc.identifier.issn | 2044-6055 | |
| dc.identifier.uri | 10.1136/bmjopen-2021-057941 | |
| dc.identifier.uri | http://hdl.handle.net/10566/7588 | |
| dc.description.abstract | Tuberculosis (TB) remains a deadly challenge globally
and Brazil, Russia, India, China and South Africa (BRICS)
are among the countries with the highest TB burden.
The objective of this study is to identify and describe
ongoing, planned and completed TB trials conducted
in the BRICS countries registered in WHO-International
Clinical Trial Registry Platform (WHO-ICTRP); to report
selective outcome reporting by comparing primary
outcomes in published trials with their prespecified
outcomes in registry records and to evaluate the time to
publication. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | BMJ Publishing Group | en_US |
| dc.subject | Clinical trials | en_US |
| dc.subject | Tuberculosis | en_US |
| dc.subject | Sustainable Development Goals | en_US |
| dc.subject | BRICS | en_US |
| dc.subject | Public health | en_US |
| dc.title | Planned, ongoing and completed tuberculosis treatment trials in Brazil, Russia, India, China and South Africa: A 2019 cross-sectional descriptive analysis | en_US |
| dc.type | Article | en_US |
